Cargando…

A phase III, randomized, open-label study of ASP8273 versus erlotinib or gefitinib in patients with advanced stage IIIB/IV non-small-cell lung cancer

BACKGROUND: ASP8273, a novel, small molecule, irreversible tyrosine kinase inhibitor (TKI) specifically inhibits the epidermal growth factor receptor (EGFR) in patients with activating mutations or EGFR T790M resistance mutations. The current study examines the efficacy, safety, and tolerability of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kelly, R J, Shepherd, F A, Krivoshik, A, Jie, F, Horn, L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6736319/ https://www.ncbi.nlm.nih.gov/pubmed/31070709 http://dx.doi.org/10.1093/annonc/mdz128

Ejemplares similares

Clinical activity of ASP8273 in Asian patients with non‐small‐cell lung cancer with EGFR activating and T790M mutations
por: Murakami, Haruyasu, et al.
Publicado: (2018)

Impact of EMT in stage IIIB/IV NSCLC treated with erlotinib and bevacizumab when compared with cisplatin, gemcitabine and bevacizumab
por: Villalobos, Matthias, et al.
Publicado: (2019)

A Phase I/III, multicenter, open-label trial of talimogene laherparepvec (T-VEC) in combination with pembrolizumab for the treatment of unresected, stage IIIb-IV melanoma (MASTERKEY-265)
por: Long, Georgina V, et al.
Publicado: (2015)

Predicting Tumor Responses to Gefitinib and Erlotinib
Publicado: (2005)

ASP8273 tolerability and antitumor activity in tyrosine kinase inhibitor‐naïve Japanese patients with EGFR mutation‐positive non‐small‐cell lung cancer
por: Azuma, Koichi, et al.
Publicado: (2018)

Correction: Predicting Tumor Responses to Gefitinib and Erlotinib
Publicado: (2012)

Treatment of stage IIIb/IV non-small cell lung cancer with Pemetrexed plus Oxaliplatin after failure of Erlotinib as second-line treatment
por: Shi, Sheng-Bin, et al.
Publicado: (2013)

Erlotinib plus tivantinib versus erlotinib alone in patients with previously treated stage IIIb/IV non–small-cell lung cancer: A meta-analysis based on randomized controlled trials
por: Deng, Huan, et al.
Publicado: (2020)

Successful erlotinib rechallenge after both gefitinib- and erlotinib-induced interstitial lung diseases
por: Arakawa, Nobuhito, et al.
Publicado: (2013)

KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
por: Pao, William, et al.
Publicado: (2005)

Efficacy of gefitinib or erlotinib in patients with squamous cell lung cancer
por: Song, Zhengbo, et al.
Publicado: (2013)

Case of Proteinuria, Worsening Hypertension, and Glomerular Endotheliosis With Erlotinib and Gefitinib
por: Latcha, Sheron, et al.
Publicado: (2018)

Comparison of afatinib and erlotinib combined with bevacizumab in untreated stage IIIB/IV epidermal growth factor receptor-mutated lung adenocarcinoma patients: a multicenter clinical analysis study
por: Lee, Suey-Haur, et al.
Publicado: (2022)

Control of Moderate-to-Severe Plaque Psoriasis with Efalizumab: 24-Week, Open-Label, Phase IIIb/IV Latin American Study Results
por: Stengel, Fernando M, et al.
Publicado: (2009)

Successful Erlotinib Treatment for a Patient with Gefitinib-Related Hepatotoxicity and Lung Adenocarcinoma Refractory to Intermittently Administered Gefitinib
por: Nagano, Tatsuya, et al.
Publicado: (2011)

Response to gefitinib and erlotinib in Non-small cell lung cancer: a retrospective study
por: Emery, Ivette F, et al.
Publicado: (2009)

Treatment with gefitinib after erlotinib-induced liver injury: a case report
por: Nakatomi, Katsumi, et al.
Publicado: (2011)

Erlotinib and gefitinib treatments of the lung cancer in an elderly patient result in gastrointestinal bleeding
por: Bai, Hongmei, et al.
Publicado: (2013)

Shikonin sensitizes wild-type EGFR NSCLC cells to erlotinib and gefitinib therapy
por: Li, Yang-Ling, et al.
Publicado: (2018)

A Phase II, Open-Label Study of Ramucirumab in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Patients with Stage IIIB/IV Non–Small-Cell Lung Cancer
por: Camidge, D. Ross, et al.
Publicado: (2014)

In vivo evaluation of an innovative synbiotics on stage IIIb-IV chronic kidney disease patients
por: Vacca, Mirco, et al.
Publicado: (2023)

Gefitinib or Erlotinib as Maintenance Therapy in Patients with Advanced Stage Non-Small Cell Lung Cancer: A Systematic Review
por: Chen, Xiaofeng, et al.
Publicado: (2013)

In Vitro and In Vivo Evaluation of (89)Zr-DS-8273a as a Theranostic for Anti-Death Receptor 5 Therapy
por: Burvenich, Ingrid J.G., et al.
Publicado: (2016)

A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations
por: Yang, J J, et al.
Publicado: (2017)

The effect of combined treatment with sodium phenylbutyrate and cisplatin, erlotinib, or gefitinib on resistant NSCLC cells
por: Al-Keilani, Maha S, et al.
Publicado: (2018)

Aspartames Alter Pharmacokinetics Parameters of Erlotinib and Gefitinib and Elevate Liver Enzymes in Wistar Rats
por: AlRasheed, Hajer, et al.
Publicado: (2022)

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
por: Pao, William, et al.
Publicado: (2005)

Assessing the Impact of Efalizumab on Nail, Scalp and Palmoplantar Psoriasis and on Quality of Life: Results from a Multicentre, Open-label, Phase IIIb/IV Trial
por: Katsambas, Andreas, et al.
Publicado: (2009)

First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study
por: Douillard, J-Y, et al.
Publicado: (2014)

Analysis of Staged Treatment for Gustilo Anderson IIIB/C Open Tibial Fractures
por: Hu, Rui, et al.
Publicado: (2018)

Recombinant Mutated Human TNF in Combination with Chemotherapy for Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Phase III Study
por: Ma, Xiaowen, et al.
Publicado: (2015)

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial
por: Schuler, M., et al.
Publicado: (2016)

Brain metastasis effectively treated with erlotinib following the acquisition of resistance to gefitinib: a case report
por: Ohara, Sayaka, et al.
Publicado: (2014)

A comparative study on erlotinib & gefitinib therapy in non-small cell lung carcinoma patients
por: Thomas, Preenumol, et al.
Publicado: (2019)

Proton pump inhibitors reduce the survival of advanced lung cancer patients with therapy of gefitinib or erlotinib
por: Lee, Chia-Han, et al.
Publicado: (2022)

A phase II open-label multicenter study of gefitinib in combination with irradiation followed by chemotherapy in patients with inoperable stage III non-small cell lung cancer
por: Levy, Antonin, et al.
Publicado: (2016)

Tapering Canakinumab Monotherapy in Patients With Systemic Juvenile Idiopathic Arthritis in Clinical Remission: Results From a Phase IIIb/IV Open‐Label, Randomized Study
por: Quartier, Pierre, et al.
Publicado: (2020)

Prediction of sensitivity to gefitinib/erlotinib for EGFR mutations in NSCLC based on structural interaction fingerprints and multilinear principal component analysis
por: Zou, Bin, et al.
Publicado: (2018)

Erratum: Recombinant Mutated Human TNF in Combination with Chemotherapy for Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Phase III Study
por: Ma, Xiaowen, et al.
Publicado: (2018)

Bioelectrical impedance phase angle in clinical practice: implications for prognosis in stage IIIB and IV non-small cell lung cancer
por: Gupta, Digant, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_nnno6ttq24faa0i4p4cg2trj42